{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:11:16Z","timestamp":1782843076363,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41409-025-02581-7","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:01:07Z","timestamp":1745247667000},"page":"994-1001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Feasibility and efficacy of partial replacement of post transplantation cyclophosphamide with bendamustine on day +4 for graft versus host disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8710-1925","authenticated-orcid":false,"given":"Velu","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manthan","family":"Kathrotiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaykumar","family":"Shirure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Bhise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Kheni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayani","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhara","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grishma","family":"Sukhwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitrangi","family":"Paranjape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Warman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Patrikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-6585","authenticated-orcid":false,"given":"Uday","family":"Yanamandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"2581_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","volume":"39","author":"L Luznik","year":"2012","unstructured":"Luznik L, O\u2019Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683\u201393.","journal-title":"Semin Oncol"},{"key":"2581_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3324\/haematol.2016.144139","volume":"102","author":"SR McCurdy","year":"2017","unstructured":"McCurdy SR, Kasamon YL, Kanakry CG, Bola\u00f1os-Meade J, Tsai HL, Showel MM, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica 2017;102:391\u2013400.","journal-title":"Haematologica"},{"key":"2581_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","volume":"11","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, et al. Posttransplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWPEBMT. J Hematol Oncol. 2018;11:40.","journal-title":"J Hematol Oncol"},{"key":"2581_CR4","doi-asserted-by":"publisher","first-page":"45.e1","DOI":"10.1016\/j.jtct.2021.09.020","volume":"28","author":"B George","year":"2022","unstructured":"George B, Kulkarni U, Lionel S, Devasia AJ, Aboobacker FN, Lakshmi KM, et al. Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complications-A single center experience from India. Transpl Cell Ther 2022;28:45.e1\u201345.e8.","journal-title":"Transpl Cell Ther"},{"key":"2581_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.bbmt.2018.12.142","volume":"25","author":"OR Copelan","year":"2019","unstructured":"Copelan OR, Sanikommu SR, Trivedi JS, Butler C, Ai J, Ragon BK, et al. Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation. Biol Blood Marrow Transpl. 2019;25:785\u201390.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2581_CR6","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1182\/blood.V130.Suppl_1.4494.4494","volume":"130","author":"MM Al Malki","year":"2017","unstructured":"Al Malki MM, Dadwal S, Yang D, Mokhtari S, Cao T, Gendzekhadze K, et al. High Incidence of CMV reactivation after haploidentical donor hematopoietic cell transplantation using high-dose post-transplant cyclophosphamide, and its impact on transplant outcomes. Blood 2017;130:4494. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.4494.4494.","journal-title":"Blood"},{"key":"2581_CR7","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/cancers13071702","volume":"13","author":"J Stokes","year":"2021","unstructured":"Stokes J, Molina MS, Hoffman EA, Simpson RJ, Katsanis E. Immunomodulatory effects of bendamustine in hematopoietic cell transplantation. Cancers. 2021;13:1702. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8038415\/.","journal-title":"Cancers"},{"key":"2581_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.14034","volume":"174","author":"J Stokes","year":"2016","unstructured":"Stokes J, Hoffman EA, Zeng Y, Larmonier N, Katsanis E. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. Br J Haematol. 2016;174:102\u201316.","journal-title":"Br J Haematol"},{"key":"2581_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/jha2.20","volume":"1","author":"E Katsanis","year":"2020","unstructured":"Katsanis E, Maher K, Roe DJ, Simpson RJ. Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation. EJHaem. 2020;1:286\u201392.","journal-title":"EJHaem"},{"key":"2581_CR10","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Centuri\u00f3n I, Gallardo Morillo AI, P\u00e9rez Mart\u00ednez A, Cabrero Calvo M, Chinea A, Gonz\u00e1lez L, et al. Sinusoidal Obstruction Syndrome\/Veno-Occlusive Disease after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with PostTransplantation Cyclophosphamide: A Study on Behalf of the Spanish Hematopoietic Stem Cell Transplantation and Cellular Therapy Group (GETH). Transpl Cell Ther. 2024;30:914.e1-914.e8. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666636724004408.","DOI":"10.1016\/j.jtct.2024.06.003"},{"key":"2581_CR11","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1182\/blood.V130.Suppl_1.3226.3226","volume":"130","author":"R Kumar","year":"2017","unstructured":"Kumar R, Kapoor R, Das SR, Yanamandra U, Pramanik S, Sharma S, et al. Cyclophosphamide Followed By Intravenous Busulfan (Cy-Bu) As Myeloablative Conditioning: Impact on Venoocclusive Disease and Transplant Outcomes, Real World Experience. Blood 2017;130:3226. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.3226.3226.","journal-title":"Blood"},{"key":"2581_CR12","doi-asserted-by":"publisher","first-page":"390.e1","DOI":"10.1016\/j.jtct.2022.04.015","volume":"28","author":"E Katsanis","year":"2022","unstructured":"Katsanis E, Stea B, Kovacs K, Truscott L, Husnain M, Khurana S, et al. Feasibility and efficacy of partially replacing post-transplantation cyclophosphamide with bendamustine in pediatric and young adult patients undergoing Haploidentical Bone Marrow Transplantation. Transpl Cell Ther 2022;28:390.e1\u2013390.e10.","journal-title":"Transpl Cell Ther"},{"key":"2581_CR13","doi-asserted-by":"publisher","first-page":"601.e1","DOI":"10.1016\/j.jtct.2021.03.032","volume":"27","author":"I Moiseev","year":"2021","unstructured":"Moiseev I, Bondarenko S, Morozova E, Vlasova Y, Dotsenko A, Epifanovskaya O, et al. Graft-versus-host disease prophylaxis with post-transplantation bendamustine in patients with refractory acute leukemia: a dose-ranging study. Transpl Cell Ther. 2021;27:601.e1\u2013601.e7.","journal-title":"Transpl Cell Ther"},{"key":"2581_CR14","unstructured":"Definition of EFS - NCI Dictionary of Cancer Terms - NCI [Internet]. 2011 [cited 2025 Jan 23]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/efs"},{"key":"2581_CR15","doi-asserted-by":"crossref","unstructured":"Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E, editors. The EBMT Handbook: Hematopoietic cell transplantation and cellular therapies [Internet]. Cham: Springer International Publishing; 2024 [cited 2024 Dec 11]. Available from: https:\/\/link.springer.com\/10.1007\/978-3-031-44080-9.","DOI":"10.1007\/978-3-031-44080-9"},{"key":"2581_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","volume":"27","author":"CL Kitko","year":"2021","unstructured":"Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transpl Cell Ther 2021;27:545\u201357.","journal-title":"Transpl Cell Ther"},{"key":"2581_CR17","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIHCIBMTR Task Force position statement on standardized terminology & guidance for graft versus-host disease assessment. Bone Marrow Transpl. 2018;53:1401\u201315.","journal-title":"Bone Marrow Transpl"},{"key":"2581_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","volume":"53","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transpl. 2018;53:521\u201334.","journal-title":"Bone Marrow Transpl"},{"key":"2581_CR19","doi-asserted-by":"crossref","unstructured":"Ibrahim U, Keyzner A Daratumumab for donor-specific anti-HLA antibody desensitization in a case of HLA-mismatched allogeneic stem cell transplantation. Hematol Transfus Cell Ther. 2022; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2531137922000086.","DOI":"10.1016\/j.htct.2021.11.019"},{"key":"2581_CR20","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood.V85.10.2742.bloodjournal85102742","volume":"85","author":"RJ Jones","year":"1995","unstructured":"Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995;85:2742\u20136.","journal-title":"Blood"},{"key":"2581_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309\u201317.","journal-title":"Clin Cancer Res"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02581-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T03:05:57Z","timestamp":1751857557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02581-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2581"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02581-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}